Compare DexCom, Inc. (DXCM) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Xcel Energy Inc — how do they compare? DexCom, Inc. trades at $83.6 (market cap $31.86B), while Xcel Energy Inc trades at $73.64 (market cap $45.82B). The key difference: Xcel Energy Inc is the larger of the two by market cap, and Xcel Energy Inc pays a 3.23% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Xcel Energy Inc for 61 Days on average.
| DXCM | XEL | |
|---|---|---|
Market Cap | $31.86B | $45.82B |
Volume | 3,607,070 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $92.34 | $83.91 |
52-Week Low | $54.84 | $69.39 |
Typical Hold Time | 62 Days | 61 Days |
Enterprise Value | $31.32B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Xcel Energy (XEL) trades at $73.46, up 1.44% today, with a bullish technical signal and consensus analyst target of $90.83 suggesting 24% upside. Recent earnings show mixed beats, with Q2 2026 EPS of $0.93 exceeding expectations. The company maintains solid profitability with a 15.28% net margin and benefits from rising data center power demand, though it faces capital expenditure pressures with a $60 billion investment plan.
The outlook is positive, driven by infrastructure investments and load growth, but risks include high debt levels, wildfire liabilities, and interest rate sensitivity. Wall Street sentiment is bullish with 63% buy ratings, but valuation concerns persist with a P/E of 20.1 above some peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
